STY12, a Novel NQO1/HDAC Dual-Targeting Agent, Exhibits Potent Anti-Pancreatic Cancer Activity by ROS-Mediated DNA...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Pancreatic cancer (PC) has poor survival rates and limited treatment options.
• Reactive oxygen species (ROS) are crucial in HDAC inhibitor action, enhancing sensitivity and overcoming resistance.
• NQO1-bioactivatable drugs are effective ROS generators, offering a strategy to improve HDAC inhibitor efficacy.

Purpose of the Study:

• To develop and evaluate a novel NQO1/HDAC dual-targeting agent, STY12, for pancreatic cancer treatment.
• To investigate STY12's mechanism of action, focusing on ROS generation and DNA damage.
• To assess STY12's efficacy and safety in preclinical pancreatic cancer models.

Main Methods:

• Synthesis and characterization of the NQO1/HDAC dual-targeting agent STY12.
• In vitro assessment of HDAC1 and HDAC6 inhibition, NQO1 bioactivation, and anti-proliferative effects on pancreatic cancer cell lines.
• Mechanistic studies involving ROS generation, DNA damage assessment, cell cycle analysis, metastasis inhibition, and apoptosis induction.
• In vivo evaluation of STY12's antitumor activity and toxicity compared to existing agents.

Main Results:

• STY12 potently inhibited HDAC1 and HDAC6 (IC50 = 29 nM and 10 nM) and showed excellent NQO1 bioactivation.
• STY12 exhibited significant anti-proliferative effects against PC cell lines (IC50 values 0.14-0.25 μM) with lower toxicity to normal cells.
• Mechanistic studies confirmed STY12 induces ROS-mediated DNA damage, cell cycle arrest (S phase), inhibits metastasis, and promotes apoptosis.
• STY12 demonstrated prominent in vivo antitumor activity with negligible toxic effects compared to SAHA and β-Lap.

Conclusions:

• STY12 is a novel NQO1/HDAC dual-targeting agent with potent anti-pancreatic cancer activity.
• Its efficacy is mediated through ROS generation, DNA damage, and modulation of cell proliferation, metastasis, and apoptosis.
• STY12 shows promise as an effective therapeutic agent for pancreatic cancer with a favorable safety profile.